European Medicines Agency rejects call for insulin review
The European Medicines Agency has rejeccted a call by the European Association for the Study of Diabetes for an investigation into a link between insulin glargine treatment and the development of cancer.
In July four papers and an editorial in Diabetologia concluded the link 'required further investigation'.
But a review by the agency's Committee for Medicine Products for Human Use concluded 'the available data does not provide a cause for concern and changes to prescribing advice are unnecessary.'
Professor Stuart Pocock, professor of epidemiology at the London School of Hygiene and Tropical Medicine, wrote in The Lancet that the trials had been methodologically flawed and may have caused patients 'unnecessary alarm and anxiety.'